DrugPatentWatch Database Preview

Details for Patent: 7,473,761

« Back to Dashboard

Which drugs does patent 7,473,761 protect, and when does it expire?

Patent 7,473,761 protects SIGNIFOR LAR and SIGNIFOR and is included in two NDAs.

This patent has forty-two patent family members in thirty-three countries.

Summary for Patent: 7,473,761

Title:	Somatostatin analogues
Abstract:	The invention provides cyclo[{4-(NH.sub.2--C.sub.2H.sub.4--NH--CO--O--)Pro}-Phg-DTrp-Lys-Tyr(4-B- enzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
Inventor(s):	Albert; Rainer (Basel, CH), Bauer; Wilfried (Lampenberg, CH), Bodmer; David (Klingnau, CH), Bruns; Christian (Freiburg, DE), Felner; Ivo (Reinach, CH), Hellstern; Heribert (Heitersheim, DE), Lewis; Ian (Riehen, CH), Meisenbach; Mark (Durmenach, FR), Weckbecker; Gisbert (Biel-Benken, CH), Wietfeld; Bernhard (Efringen-Kirchen, DE)
Assignee:	Novartis AG (Basel, CH)
Application Number:	10/343,288
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 7,473,761

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Novartis Pharms Corp	SIGNIFOR LAR	pasireotide pamoate	POWDER;INTRAMUSCULAR	203255-001	Dec 15, 2014		RX	Yes	No			Y	Y
Novartis Pharms Corp	SIGNIFOR LAR	pasireotide pamoate	POWDER;INTRAMUSCULAR	203255-002	Dec 15, 2014		RX	Yes	No			Y	Y
Novartis Pharms Corp	SIGNIFOR LAR	pasireotide pamoate	POWDER;INTRAMUSCULAR	203255-003	Dec 15, 2014		RX	Yes	Yes			Y	Y
Novartis	SIGNIFOR	pasireotide diaspartate	SOLUTION;SUBCUTANEOUS	200677-001	Dec 14, 2012		RX	Yes	No			Y	Y

Foreign Priority and PCT Information for Patent: 7,473,761

PCT Information
PCT Filed	July 30, 2001	PCT Application Number:	PCT/EP01/08824
PCT Publication Date:	February 07, 2002	PCT Publication Number:	WO02/10192

Non-Orange Book US Patents Family Members for Patent 7,473,761

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,035,021	Somatostatin analogues
7,939,625	Somatostatin analogues
8,822,637	Somatostatin analogues

International Patents Family Members for US Patent 7,473,761

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Czech Republic	20030288
Canada	2416293
China	1446229
China	1267451